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Background: Whole-ventricular radiotherapy (WV-RT) followed by a boost to the tumor bed (WV-RT/TB)
is recommended for intracranial germ cell tumors (IGCT). As the critical brain areas are mainly in the
target volume vicinity, it is unclear if protons indeed substantially spare neurofunctional organs at risk
(NOAR). Therefore, a dosimetric comparison study of WV-RT/TB was conducted to assess whether proton
or photon radiotherapy achieves better NOAR sparing.
Methods: Eleven children with GCT received 24 Gy(RBE) WV-RT and a boost up to 40 Gy(RBE) in 25
fractions of 1.6 Gy(RBE) with pencil beam scanning proton therapy (PBS-PT). Intensity-modulated radio-
therapy (IMRT) and volumetric-modulated arc therapy (VMAT) plans were generated for these patients.
NOAR were delineated and treatment plans were compared for target volume coverage (TVC), homogene-
ity index (HI), inhomogeneity coefficient (IC) and (N)OAR sparing.
Results: TVC was comparable for all three modalities. Compared to IMRT and VMAT, PBS-PT showed
statistically significant optimized IC, as well as dose reduction, among others, in mean and integral dose
to the: normal brain (–35.2%, –32.7%; 35.2%, –33.0%, respectively), cerebellum (–53.7%, –33.1%; –53.6%,
–32.7%) and right temporal lobe (–14.5%, 31.9%; 14.7%, 29.9%). The Willis’ circle was better protected
with PBS-PT than IMRT (7.1%; 7.8%). The left hippocampus sparing was higher with IMRT. Compared
to VMAT, the dose to the hippocampi, amygdalae and temporal lobes was significantly decreased in the
IMRT plans.
Conclusions: Dosimetric comparison of WV-RT/TB in IGCT suggests PBS-PT’s advantage over photons in
conformality and NOAR sparing, whereas IMRT’s superiority over VMAT, thus potentially minimizing
long-term sequelae.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Intracranial germ cell tumors (IGCT) represent a histologically
heterogeneous pediatric group of primary predominantly midline
tumors of the CNS, most commonly seen in the pineal and the
suprasellar region [1,2], classically divided into two main groups:
germinomas – the most common –, and non-germinomatous
GCT, which carry a less favorable prognosis [3,4]. Germinomas
are highly sensitive to both chemotherapy and radiotherapy (RT),
and curable by RT alone [1,2,4], either photons or protons [5]. They
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years after RT alone, 100% and 80.6% at 10- and 20-years, respec-
tively [1,6,7]. Macdonald showed early clinical outcomes of IGCT
patients treated with protons where local control, progression-
free survival, and overall survival rates were, respectively, 100%,
95%, and 100%, at a median follow-up of 28 months [8]. Whole ven-
tricular system irradiation followed by a boost to the tumor bed
(WV-RT/TB) is considered a well-established treatment for local-
ized germinomas{MacDonald, 2003 #259} [8].
There has been an effort for treatment de-escalation, due to:
first, good response rates to neoadjuvant chemotherapy in non-
disseminated disease [9], with low leptomeningeal recurrence
[1]; second, noteworthy toxicity in long-term survivors [7]. How-
ever, evaluating cerebral toxicity is extremely difficult as we only
begin to understand the intricate interplay between the different
substructures in physiological conditions, let alone in pathological
conditions [10]. Nonetheless, studies of Merchant et al. [11]
demonstrated that radiation dose-volume parameters remain the
most clinically significant determinants of intelligence quotient
(IQ) outcomes and that further reduction in radiation dose to speci-
fic volumes of the brain should be pursued [12]. Relative to pho-
tons, hadron therapy could achieve even better protection of
healthy tissues by improved beam trajectory [8], having the poten-
tial to prevent the genesis of radiogenic impairment [13], thus
being expected to reduce late effects without decreasing local con-
trol and survival [5].
However, taking into account that most of the neurofunctional
organs at risk (NOAR) are partly enclosed or in the direct vicinity of
the target, we hypothesized that there would not be a dosimetric
advantage of pencil beam scanning proton therapy (PBS-PT) over
a state of the art photon treatment technique. To the best of our
knowledge, no dosimetric comparison based on WV-RT/TB has
yet been made between PBS-PT and photon RT for non-
metastatic IGCT with focus on NOAR sparing. Therefore, we
performed a planning study with the aim of determining the
dosimetric difference between intensity-modulated radiotherapy
(IMRT) and volumetric-modulated arc therapy (VMAT) on a cohort
of IGCT patients treated with PBS-PT WV-RT/TB, using dose-
volume indices of target volume coverage (TVC) and (N)OAR.
Hereby, we compared the sparing potential of NOAR, currently
used as a surrogate for neurocognition, cerebrovascular and neu-
roendocrine function, as well as other important structures, such
as optic apparatus and cochleae, delineated on a routine basis for
the planning of brain tumors RT.2. Materials and methods
2.1. Patient selection
Between 2005 and 2017, 11 patients (8 males; 6–16 years, med-
ian 11) with a histologically proven diagnosis of localized IGCT
were treated, after multi-agent chemotherapy, with PBS-PT at the
Centre for Proton Therapy at the Paul-Scherrer Institute (PSI). They
consisted of 2 bifocal germinomas, 4 pineal, 2 suprasellar, while 3
IGCT presented an atypical location with infiltrative spread within
the ventricular system. Written, informed consent to the PBS-PT
was obtained from the children legal guardians. Institutional
review board approval was obtained before record and plan
review. Complete anonymity of names and medical record num-
bers was maintained.2.2. Target volume and organ at risk delineation
First, all the 11 treatment planning-CTs and pre-irradiation MRI
studies were anonymized and imported into a research database ofVelocity (version 3.2.1, Varian Medical Systems, Inc., Palo Alto,
USA). The MRIs were anatomically registered to the CT to facilitate
volume definition. Then, for each patient, all volumes of interest
(VOI) were delineated or adapted by a single radiation oncologist
and reviewed by a neuro-radiation oncologist, as well as one neu-
roradiologist. For the purpose of this study, a 3 mm isometric mar-
gin, created on the same treatment planning software (TPS), was
used for both planning treatment volumes (PTV). Delineation
guidelines of the target volumes [14] and (N)OAR [15], as well as
their dose constraints are detailed in the supplementary file A.
2.3. Treatment planning
The planning-CT data was sent in DICOM format, and all data
transfers were made using file transfer protocol over Internet con-
nections. The same VOI, dose prescription, and constraints were
used to ensure comparability among the plans. The WV/TB were
prescribed 24 Gy (PTV_Low), followed by a boost of 16 Gy to the
TB (PTV_High), achieving a total dose of 40 Gy in 1.6 Gy per frac-
tion. The plans were normalized to get 100% of the prescribed dose
(Dp) as the mean dose to each PTV. All treatment plans were opti-
mized to maximize TVC whilst sparing OAR. Besides the hip-
pocampi and temporal lobes, no further fixed constraint was set
for the NOAR than the as low as reasonably achievable (ALARA)
concept [10], due to its location towards the target and lack of con-
sensual constraints.
After trying and comparing different beam arrangements, all
patients were treated with PBS-PT with three non-coplanar proton
fields for both treatment series, with different gantry angulations
and table rotation. Similar field arrangements have been used for
the first phase and an adapted one for the boost (example in
Fig. 1): one posterior field (G180deg, couch 0), two superior obli-
que fields (G90deg, couch 315–325 and G270deg, couch 35–45),
in IEC61217 coordinate convention. All PBS-PT cases were planned
with single field uniform dose, using the PSIPlan TPS (version 2.9.1-
exp). The generic relative biologic effectiveness (RBE) factor for
protons of 1.1 (relative to 60Co) was utilized, and proton dose
was expressed in terms of Gy(RBE) (i.e., Gy(RBE) = proton physical
Gy  1.1) [16]. The ion source was a dedicated 250 MeV cyclotron.
Protons were actively delivered using a PBS paradigm, as previ-
ously described [17]. Individual weights of the Bragg peak were
computed using a dose based optimization scheme [18] to obtain
an optimal TVC. Proton dose calculation was performed using a
3D dose-calculation algorithm developed at PSI [19].
Comparison planning with IMRT and VMAT was performed on
the original anonymized planning CT datasets and its respective
study VOI. For the IMRT planning, after comparing with other
beam arrangements, seven fields were used for the primary and
five for the boost phase. The dose distribution of the photon plans
was calculated with the Anisotropic Analytical Algorithm version
13.6.23, and optimized with the Dose Volume Optimizer version
11.0.31, on the Eclipse External Beam Planning (same version as
described in 2.2).
2.4. Comparative evaluation of treatment plans
The proton plans were imported to Eclipse for comparison with
the photon plans, where they were quantitatively assessed using
dose-volume histograms (DVH) for all VOI. Dose parameters were
extracted to evaluate proper TVC, assure compliance with the OAR
dose constraints and determine differences between all RT modal-
ities. TVC was assessed by the evaluation of the volume receiving a
minimum of 90%, 95%, and 100% of the prescribed doses (V90%, V95%,
V100%, respectively) [13,20]. Dose distribution in the PTV was eval-
uated with the homogeneity index (HI) and inhomogeneity coeffi-
cient (IC). The integral dose (ID) (Supplementary file) allows the
Fig. 1. Comparison of dose distribution in three different modalities for a patient with intracranial germ cell tumor: (A) Pencil beam scanning proton beam therapy (PBS-PT)
plan. (B) Intensity-modulated radiotherapy (IMRT) plan. (C) Volumetric modulated arc therapy (VMAT) plan. PTV_Low is delineated in orange, PTV_High in red. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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measurements [21].
2.5. Statistics
Statistical analysis was performed on IBM SPSS Statistics soft-
ware, version 24 (Armonk, NY). Descriptive statistics were used to
calculate the differences in treatment parameters of proton and
photon therapy. The Friedman test with the Bonferroni posttest
was applied for analysis of statistically significant differences
between several dosimetric parameters of the targets and (N)
OAR of the proton and photon plans, with corresponding two-
sided 95% confidence intervals to correct for multiple comparisons.
A p-value inferior to 0.017 (Bonferroni correction) was considered
statistically significant.
3. Results and discussion
3.1. Target volume coverage
Despite the normalization of each PTV (see 2.3), after extracting
the DVH values automatically with an Eclipse protocol template, a
technical deviation 0.25% could be seen (Table 1) if performed on
another TPS than where it was planned. Therefore, the PBS-PT
results should be critically appraised with the same amount of
uncertainty. For this reason, only higher deviations (>0.25%), statis-
tically significant (p < 0.017), will be mentioned.
TVC was comparable for all three modalities (Fig. 2). However,
PBS-PT achieved a better V100% (22.5%) in PTV_High, compared to
VMAT.
Comparing to IMRT and VMAT, both PTV showed with PBS-PT a
higher minimum dose (Dmin) to the PTV (PTV_Low: 26.4%, 18.2%;PTV_High: 15.9%, 7.8%). Both IC were significantly lower for pro-
tons (PTV_Low: 50.0%, –33.3%; PTV_High: 44.8%, 30.4%), indi-
cating a lower variability of the target dose distribution in PBS-PT
than in the photon modalities.
The dose distribution homogeneity on the primary phase was
optimized in the VMAT plans, as the PTV_Low HI was significantly
lower than the other RT techniques, while PBS-PT was better than
IMRT on the boost phase (Table 1).
3.2. Neurofunctional organ at risk sparing
For the OARs, 100% was considered to be 40 Gy (Table 1). All
hard constraints were met, independently of the technique used.
3.2.1. NOAR of neurocognitive function
The hippocampal and amygdalae Dmean and ID seem better
spared with IMRT than VMAT, while on the left hippocampus the
IMRT dose sparing seems higher than with the remaining tech-
niques (6.2% Dmean, 6.1% ID than PBS-PT; 10.8% Dmean and ID
each, comparing with VMAT). However, taking into account the
hippocampal proximity to the target, its soft constraint of D40%
7.3 Gy could never be reached – its lowest absolute dose was
24.2 Gy on one PBS-PT plan.
There is growing evidence from structural and functional imag-
ing studies that the cerebellum plays an evident role in neurocog-
nition. Radiation to the posterior fossa has shown to have a
negative effect on neurocognitive outcomes in long-term pediatric
brain survivors [12]. Gan et al. described that the patient with the
lowest neuropsychological scores received 36 Gy Dmax on the cere-
bellum and low radiation doses on the whole brain and hip-
pocampi [22]. In our cohort, only one case (PBS-PT) achieved a
Dmax < 36 Gy, otherwise, the PBS-PT average was 39.6 Gy (range,
Table 1
Comparison of target volume coverage and normal tissue sparing between PBS-PT, IMRT and VMAT.
VOI Parameter PBS-PT IMRT VMAT PBS-PT vs.
IMRT (%)
PBS-PT vs.
VMAT (%)
IMRT vs.
VMAT (%)
PTV_Low Dmax (%) 106.8 ± 1.3 107.0 ± 1.7 107.2 ± 0.8 0.2 0.4 0.2
Dmean (%) 100.3 ± 0.6 100.0 ± 0.0 100.0 ± 0.0 0.2 0.2 0.0
Dmin (%) 89.0 ± 2.0 70.4 ± 11.1 75.3 ± 10.2 26.4* 18.2* 6.5
Mean ID (Gy.ml) 7620.8 ± 3572.9 7608.4 ± 3578.9 7608.4 ± 3578.9 0.2 0.2 0.0
Coverage
V90% (%) 99.9 ± 0.0 99.7 ± 0.0 99.9 ± 0.0 0.2* 0.0 0.2
V95% (%) 99.1 ± 0.0 98.7 ± 0.0 99.3 ± 0.0 0.4 0.2 0.6
V100% (%) 63.9 ± 0.1 59.7 ± 0.2 55.2 ± 0.0 7.0 15.8 8.2
Dose distribution
HI 4.9 ± 0.5 5.5 ± 1.5 3.5 ± 0.6 10.9 40.0* 57.1*
IC 0.2 ± 0.0 0.4 ± 0.1 0.3 ± 0.1 50.0* –33.3* 33.3
PTV_High Dmax (%) 104.7 ± 1.6 105.8 ± 2.1 106.1 ± 1.5 1.0 1.3 0.3
Dmean (%) 100.1 ± 0.1 100.0 ± 0.0 100.0 ± 0.0 0.1* 0.1* 0.0
Dmin (%) 89.4 ± 2.8 77.1 ± 7.4 82.9 ± 3.9 15.9* 7.8* 7.0*
Mean ID (Gy.ml) 1909.1 ± 2346.4 1907.4 ± 2345.1 1907.4 ± 2345.1 0.1* 0.1* 0.0
Coverage
V90% (%) 99.7 ± 0.0 99.3 ± 0.0 99.9 ± 0.0 0.4 0.2 0.6
V95% (%) 98.4 ± 0.0 93.5 ± 0.2 98.2 ± 0.0 5.2 0.2 4.8
V100% (%) 70.8 ± 0.1 55.9 ± 0.2 57.8 ± 0.0 26.7 22.5* 3.3
Dose distribution
HI 4.7 ± 1.0 6.4 ± 1.2 5.0 ± 1.4 26.6* 6.0 28.0
IC 0.2 ± 0.0 0.3 ± 0.1 0.2 ± 0.0 44.8* 30.4* 26.1
CTV_Low Dmax (%) 106.5 ± 1.1 105.9 ± 1.2 106.4 ± 1.4 0.6 0.1 0.5
Dmean (%) 100.6 ± 0.2 100.2 ± 0.1 100.2 ± 0.1 0.4* 0.4* 0.0
Mean ID (Gy.ml) 5111.7 ± 2913.9 5103.5 ± 2905.0 5092.6 ± 2905.9 0.3* 0.4* 0.0
CTV_High Dmax (%) 104.2 ± 1.2 104.5 ± 3.1 105.5 ± 1.4 0.3 1.2 0.9
Dmean (%) 100.7 ± 0.2 100.3 ± 0.2 100.3 ± 0.1 0.4* 0.4* 0.0
Mean ID (Gy.ml) 1300.6 ± 1747.2 1297.0 ± 1742.0 1298.0 ± 1745.2 0.3* 0.4* 0.1
GTV_Low Dmax (%) 104.0 ± 1.5 105.4 ± 1.3 103.3 ± 1.2 1.3 0.7 2.0*
Dmean (%) 100.3 ± 0.2 100.4 ± 0.3 100.0 ± 0.1 0.1 0.3* 0.4*
Mean ID (Gy.ml) 1975.9 ± 1717.1 1978.1 ± 1719.7 1972.0 ± 1716.6 0.1 0.2* 0.3*
GTV_High Dmax (%) 102.6 ± 1.1 103.9 ± 2.5 102.6 ± 1.1 1.3 0.0 1.3
Dmean (%) 100.6 ± 0.3 100.4 ± 0.5 100.0 ± 0.1 0.2 0.6* 0.4
Mean ID (Gy.ml) 588.6 ± 926.9 589.6 ± 929.0 588.4 ± 921.9 0.2 0.2* 0.0
Amygdala left Dmax (%) 91.4 ± 16.4 89.7 ± 15.9 93.5 ± 11.7 1.9 2.2 4.1
Dmean (%) 79.7 ± 18.2 77.0 ± 17.5 85.0 ± 14.3 3.5 6.2 9.4*
Mean ID (Gy.ml) 52.5 ± 26.6 50.8 ± 23.6 55.7 ± 22.7 3.3 5.7 8.8*
Amygdala right Dmax (%) 89.1 ± 16.1 87.6 ± 15.5 92.3 ± 11.5 1.7 3.5 5.1
Dmean (%) 79.1 ± 17.7 77.3 ± 16.8 84.4 ± 13.1 2.3 6.3 8.4*
Mean ID (Gy.ml) 60.7 ± 26.4 59.3 ± 26.1 64.4 ± 24.6 2.4 5.7 7.9*
Brainstem Dmax (%) 102.1 ± 0.6 102.6 ± 1.0 102.9 ± 0.9 0.5 0.8 0.3
Dmean (%) 74.8 ± 7.2 82.4 ± 6.0 77.3 ± 8.0 9.2* 3.2 6.6
Mean ID (Gy.ml) 706.1 ± 130.2 777.4 ± 136.0 730.4 ± 144.7 9.2* 3.3 6.4
Cerebellum Dmax (%) 99.1 ± 4.7 101.1 ± 2.7 100.1 ± 4.3 2.0 1.0 1.0
Dmean (%) 25.7 ± 3.4 55.5 ± 7.6 38.4 ± 4.3 53.7* –33.1* 44.5*
Mean ID (Gy.ml) 1423.0 ± 309.0 3069.0 ± 692.0 2115.3 ± 376.9 53.6* –32.7* 45.1*
Chiasm Dmax (%) 91.2 ± 16.1 90.3 ± 15.4 91.8 ± 13.7 0.1 0.7 1.6
5.1
4.9
Dmean (%) 73.0 ± 27.3 74.4 ± 24.7 78.4 ± 21.9 1.9 6.9
Mean ID (Gy.ml) 11.5 ± 6.0 11.6 ± 5.2 12.2 ± 5.1 0.9 5.7
Circle of Willis Dmax (%) 102.6 ± 2.2 101.2 ± 2.7 96.8 ± 20.1 1.4 6.0 4.5
Dmean (%) 63.8 ± 24.3 68.7 ± 22.0 67.5 ± 26.2 7.1* 5.5 1.8
Mean ID (Gy.ml) 85.6 ± 31.5 92.8 ± 29.6 90.5 ± 37.8 7.8* 5.4 2.5
Cochlea left Dmax (%) 21.0 ± 11.6 25.9 ± 6.6 17.0 ± 6.5 18.9 23.5 52.5*
Dmean (%) 12.0 ± 7.9 18.9 ± 4.2 13.2 ± 4.0 36.5 9.1 43.2*
33.3*
Mean ID (Gy.ml) 0.5 ± 0.3 0.8 ± 0.3 0.6 ± 0.2 40.5 20.7
Cochlea right Dmax (%) 22.8 ± 17.9 24.5 ± 6.7 17.8 ± 6.9 6.9 28.1 37.6*
Dmean (%) 13.3 ± 10.9 18.6 ± 4.2 13.5 ± 4.5 28.5 1.5 37.8*
Mean ID (Gy.ml) 0.5 ± 0.4 0.7 ± 0.2 0.5 ± 0.2 28.6 0.0 40.0*
Hippocampus left Dmax (%) 101.1 ± 0.5 101.1 ± 0.7 101.4 ± 0.5 0.0 0.3 0.3
Dmean (%) 84.5 ± 10.5 79.6 ± 11.7 89.2 ± 7.9 6.2* 5.3 10.8*
Mean ID (Gy.ml) 109.9 ± 37.9 103.6 ± 37.5 116.1 ± 37.8 6.1* 5.3 10.8*
D40% (%) 87.8 ± 13.2 84.9 ± 11.8 91.1 ± 8.0 3.4 4.4 7.5
Hippocampus right Dmax 97.5 ± 12.0 98.3 ± 8.0 99.5 ± 6.1 0.8 2.0 1.2
Dmean 79.6 ± 12.4 76.3 ± 11.7 86.4 ± 8.9 4.3 7.9 11.7*
Mean ID (Gy.ml) 110.1 ± 35.3 102.5 ± 33.6 119.6 ± 37.4 7.4 7.9 14.3*
D40% (%) 79.4 ± 14.0 78.3 ± 13.4 87.5 ± 8.9 1.4 9.3 10.5
Hypothalamus left Dmax (%) 100.9 ± 0.3 102.0 ± 1.0 101.1 ± 0.5 1.1 0.2 0.9
Dmean (%) 97.8 ± 7.8 97.8 ± 6.1 97.2 ± 6.4 0.0 0.6* 0.6
Mean ID (Gy.ml) 11.3 ± 5.6 11.3 ± 5.5 11.2 ± 5.6 0.0 0.9* 0.9
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Table 1 (continued)
VOI Parameter PBS-PT IMRT VMAT PBS-PT vs.
IMRT (%)
PBS-PT vs.
VMAT (%)
IMRT vs.
VMAT (%)
Hypothalamus right Dmax (%) 100.7 ± 1.1 101.7 ± 2.1 100.5 ± 2.9 1.0 0.2 1.2*
Dmean (%) 97.8 ± 8.1 97.9 ± 6.3 97.1 ± 7.0 0.1 0.7 0.8
Mean ID (Gy.ml) 11.6 ± 5.5 11.6 ± 5.4 11.6 ± 5.5 0.0 0.0 0.0
Lacrimal gland left Dmax (%) 6.6 ± 17.1 8.6 ± 7.2 18.5 ± 6.9 –23.3* 64.3* 53.5*
Dmean (%) 2.6 ± 7.2 5.7 ± 4.5 22.2 ± 27.0 54.4* 88.3* 74.3*
Mean ID (Gy.ml) 0.4 ± 1.2 0.9 ± 0.8 3.8 ± 5.6 57.6* 89.5* 75.2*
Lacrimal gland right Dmax (%) 1.3 ± 3.2 7.6 ± 5.8 17.7 ± 6.4 82.9* 92.7* 57.1*
Dmean (%) 0.3 ± 0.8 5.3 ± 4.3 13.5 ± 6.1 94.3* 97.8* 60.7*
Mean ID (Gy.ml) 0.0 ± 0.1 0.8 ± 0.5 2.1 ± 0.8 95.8* 98.4* 61.9*
Lens left Dmax (%) 0.4 ± 1.3 4.1 ± 2.5 10.9 ± 4.8 90.2* 96.3* 62.4*
Dmean (%) 0.2 ± 0.6 3.7 ± 2.1 9.3 ± 4.0 94.6* 97.8* 60.2*
Mean ID (Gy.ml) 0.0 ± 0.0 0.3 ± 0.2 0.8 ± 0.4 100.0* 100.0* 62.5*
Lens right Dmax (%) 0.0 ± 0.0 3.9 ± 2.1 11.1 ± 5.0 100.0* 100.0* 64.9*
Dmean (%) 0.0 ± 0.0 3.6 ± 1.9 9.4 ± 4.1 100.0* 100.0* 61.7*
Mean ID (Gy.ml) 0.0 ± 0.0 0.3 ± 0.1 0.7 ± 0.2 100.0* 100.0* 58.2*
Normal brain (brain minus PTV) Dmax (%) 100.7 ± 0.5 103.3 ± 1.6 102.3 ± 1.5 2.5* 1.6* 1.0
Dmean (%) 30.0 ± 8.6 46.3 ± 10.0 44.6 ± 9.1 35.2* –32.7* 3.8
Mean ID (Gy.ml) 12211.7 ± 3402.8 18846.4± 3924.7 18226.7± 3887.2 35.2* –33.0* 3.4
Optic globe left Dmax (%) 8.6 ± 23.6 12.0 ± 14.8 22.9 ± 12.4 28.3* 62.4* 47.6*
Dmean (%) 1.0 ± 3.2 5.2 ± 4.4 13.9 ± 6.8 80.8* 92.8* 62.6*
Mean ID (Gy.ml) 3.3 ± 10.4 16.1 ± 14.3 42.3 ± 21.4 79.5* 92.2* 61.9*
Optic globe right Dmax (%) 2.0 ± 3.5 8.9 ± 6.8 20.5 ± 0.8 77.5* 90.2* 56.6*
Dmean (%) 0.1 ± 0.2 4.7 ± 0.2 13.2 ± 6.7 97.9* 99.2* 64.4*
Mean ID (Gy.ml) 0.3 ± 0.6 14.8 ± 11.6 40.3 ± 22.4 98.2* 99.3* 63.3*
Optic nerve left Dmax (%) 65.4 ± 42.4 58.8 ± 38.2 61.3 ± 35.5 11.2 6.7 4.1
Dmean (%) 20.4 ± 22.6 24.1 ± 20.0 30.5 ± 19.2 15.4 –33.1* 21.0*
Mean ID (Gy.ml) 2.5 ± 2.4 3.2 ± 1.9 4.2 ± 1.9 21.9 40.5 –23.8*
Optic nerve right Dmax (%) 62.9 ± 38.7 56.3 ± 38.8 59.0 ± 36.0 11.7 6.6 4.6
Dmean (%) 15.7 ± 22.3 22.1 ± 19.6 28.7 ± 19.4 29.0 45.3* –23.0*
Mean ID (Gy.ml) 1.9 ± 2.1 2.9 ± 1.8 3.9 ± 1.8 34.5 51.3* 25.6*
Parotid left Dmax (%) 0.6 ± 1.8 18.2 ± 6.7 9.7 ± 2.6 96.7* 93.8* 87.6*
Dmean (%) 0.0 ± 0.0 5.9 ± 1.9 5.5 ± 1.8 100.0* 100.0* 7.3
Mean ID (Gy.ml) 0.0 ± 0.0 25.6 ± 11.9 25.5 ± 19.8 100.0* 100.0* 0.4
Parotid right Dmax (%) 0.3 ± 0.7 16.7 ± 5.9 8.9 ± 2.0 98.2* 96.6* 87.6*
Dmean (%) 0.0 ± 0.0 5.7 ± 2.1 5.1 ± 1.4 100.0* 100.0* 11.8
Mean ID (Gy.ml) 0.0 ± 0.0 24.6 ± 13.3 22.6 ± 13.2 100.0* 100.0* 8.8
Pituitary Dmax (%) 68.9 ± 32.5 63.2 ± 34.5 60.8 ± 37.4 9.0 13.3 3.9
Dmean (%) 54.5 ± 41.2 53.6 ± 39.6 53.9 ± 39.4 1.7 1.1 0.6
Mean ID (Gy.ml) 11.4 ± 15.2 11.3 ± 14.9 11.4 ± 14.9 0.9 0.0 0.9
Skin Dmax (%) 38.7 ± 25.0 46.7 ± 6.0 47.5 ± 9.7 17.1 18.5 1.7
Dmean (%) 13.8 ± 19.2 9.0 ± 2.8 8.0 ± 2.2 53.3 72.5 12.5
Mean ID (Gy.ml) 701.5 ± 774.4 612.2 ± 357.3 553.6 ± 343.3 14.6 26.7 10.6
Spinal cord Dmax (%) 54.8 ± 11.7 51.2 ± 19.4 46.1 ± 22.1 7.0 18.9 11.1
Dmean (%) 13.1 ± 8.3 12.4 ± 7.8 8.9 ± 6.5 5.6 47.2* 39.3*
Mean ID (Gy.ml) 22.2 ± 13.8 21.9 ± 14.2 15.3 ± 11.1 1.4 45.1* 43.1*
Supratentorial Dmax (%) 103.2 ± 1.6 103.9 ± 1.6 103.4 ± 1.1 0.7 0.2 0.5
Dmean (%) 39.8 ± 11.9 52.2 ± 11.9 50.2 ± 11.3 –23.8* 20.7* 4.0
Mean ID (Gy.ml) 36821.3± 65329.3 47163.9± 81511.6 46058.0 ± 80876.5 21.9* 20.1* 2.4
SVZ left Dmax (%) 99.0 ± 5.3 99.2 ± 5.8 98.6 ± 6.8 0.2 0.4 0.6
Dmean (%) 76.5 ± 11.3 75.5 ± 11.9 80.5 ± 10.7 1.3 5.0* 6.2*
Mean ID (Gy.ml) 192.7 ± 159.8 193.6 ± 167.6 202.0 ± 164.8 0.5 4.6* 4.2*
SVZ right Dmax (%) 93.6 ± 12.3 95.5 ± 11.1 96.1 ± 8.3 2.0* 2.6* 0.6
Dmean (%) 73.7 ± 11.9 73.3 ± 11.9 78.9 ± 10.5 0.5 6.6* 7.1
Mean ID (Gy.ml) 177.3 ± 148.3 179.5 ± 156.8 188.4 ± 153.0 1.2 5.9* 4.7
Temporal lobe left Dmax (%) 101.0 ± 3.7 100.9 ± 5.0 101.1 ± 4.1 0.1 0.1 0.2
Dmean (%) 49.0 ± 19.5 50.5 ± 13.4 58.8 ± 19.9 3.0* 16.7 14.1*
Mean ID (Gy.ml) 2444.9 ± 1406.6 2455.2 ± 899.2 2819.5 ± 1211.3 0.4* 13.3 12.9*
V20Gy (%) 107.4 ± 37.7 134.7 ± 55.6 177.8 ± 42.4 20.3 39.6* 24.2*
Temporal lobe right Dmax (%) 97.0 ± 10.1 97.7 ± 8.3 99.7 ± 5.8 0.7 2.7 2.0*
Dmean (%) 43.1 ± 14.0 50.4 ± 14.1 63.3 ± 12.5 14.5* 31.9* 20.4*
Mean ID (Gy.ml) 4621.6 ± 8441.5 5420.9 ± 9931.5 6588.9 ± 51.5 14.7* 29.9* 17.7*
Thalamus left V20Gy (%) 104.2 ± 36.5 137.4 ± 51.5 177.0 ± 42.0 24.2* 41.1* –22.4*
Dmax (%) 101.1 ± 0.4 102.5 ± 1.2 101.9 ± 0.6 1.4 0.8* 0.6
Dmean (%) 96.5 ± 3.6 96.2 ± 3.8 95.3 ± 5.6 0.3 1.3 0.9
Mean ID (Gy.ml) 214.8 ± 44.8 214.6 ± 47.3 211.6 ± 42.6 0.1 1.5 1.4
Thalamus right Dmax (%) 101.2 ± 0.4 102.4 ± 1.1 102.1 ± 0.8 1.2 0.9 0.3
Dmean (%) 93.4 ± 8.0 93.5 ± 6.4 94.8 ± 4.6 0.1 1.5 1.4
Mean ID (Gy.ml) 211.2 ± 44.9 211.8 ± 46.0 214.3 ± 44.4 0.3 1.4 1.2
TMJ left Dmax (%) 9.7 ± 8.7 16.5 ± 8.0 12.0 ± 4.4 44.6* 19.2 45.8*
Dmean (%) 1.0 ± 1.2 9.9 ± 3.6 8.5 ± 2.6 89.9* 88.2* 16.5
Mean ID (Gy.ml) 0.9 ± 1.3 8.1 ± 3.9 7.0 ± 3.3 88.7* 87.0* 15.7
(continued on next page)
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Table 1 (continued)
VOI Parameter PBS-PT IMRT VMAT PBS-PT vs.
IMRT (%)
PBS-PT vs.
VMAT (%)
IMRT vs.
VMAT (%)
TMJ right Dmax (%) 10.7 ± 11.8 18.0 ± 8.7 12.7 ± 4.6 40.6* 15.7 41.7*
Dmean (%) 1.3 ± 1.8 9.7 ± 4.2 8.6 ± 2.6 86.1* 83.8* 16.2
Mean ID (Gy.ml) 1.1 ± 1.6 7.9 ± 4.5 6.8 ± 3.3 86.0* 83.8* 16.2
Values are given as mean relative dose with standard deviations in percentage (%):
– Primary phase (PTV_Low, CTV_Low, GTV_Low) 24 Gy
= 100%– Boost phase (PTV_High, CTV_High, GTV_High) 16 Gy
– Organs at risk All other VOI 40 Gy
Abbreviations: VOI, volume of interest; PTV, planning target volume; Dmax, maximum dose of VOI; Dmean, average dose of VOI; Dmin, minimum dose of VOI; ID, integral dose
(Dmean  volume); V90%, percentage of PTV receiving a minimum of 90% of the prescribed dose; V95%, percentage of PTV receiving a minimum of 95% of the prescribed dose;
V100%, percentage of PTV receiving a minimum of 100% of the prescribed dose; HI, homogeneity index ((D5%  D95%)/prescribed dose  100); IC, inhomogeneity coefficient
((Dmax  Dmin)/Dmean); CTV, clinical target volume; GTV, gross tumour volume; SVZ, subventricular zone; TMJ, temporomandibular joint.
* Indicates statistically significant differences (p < 0.017) in the Friedman test with the Bonferroni posttest.
Fig. 2. Cumulative dose-volume histograms (DVH) (mean dose, n = 11) with range for PTV coverage with PBS-PT, IMRT and VMAT plans.
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IMRT and VMAT could be seen on Dmean (53.7%, –33.1%) and ID
(-53.6%, –32.7%), favoring the proton over the photon plans.
Between IMRT and VMAT, the latter seems dosimetrically benefi-
cial (44.5% Dmean; 45.1% ID) regarding cerebellum dose expo-
sure (Fig. 3).
Compared to IMRT and VMAT, PBS-PT showed the following
statistically significant reduction in:
 temporal lobe – Dmean (14.5%, 31.9%), ID (14.7%, 29.9%),
V20Gy (24.2%, 41.1%) on the right side. Moreover, the left
temporal lobe dose sparing was higher with protons (PBS-PT
Dmean, ID better than IMRT; PBS-PT V20Gy better than VMAT).
Compared to VMAT, IMRT seems advantageous in both lobes.Fig. 3. Cumulative DVH (mean dose, n = 11) with range for (N)OAR w subventricular zone (SVZ) – maximum dose (Dmax) (2.0%,
2.6%) on the right side. Furthermore, VMAT had the least dose
sparing in comparison to the other two modalities (PBS-PT
Dmean and ID better spared on both sides, while IMRT Dmean
and ID on the left side).
Neurons and glial cells are produced from neurogenic stem cells
located in the SVZ of the lateral ventricles and the subgranular
zone of the hippocampal gyrus. These areas form part of the limbic
system, located in the temporal lobe. They have important roles in
various aspects of memory and emotional learning [23] and are
very susceptible to radiation-induced damage, particularly in the
developing tissues of young patients [24]. A dose-dependent thin-
ning of the cerebral cortex was described, with a pronounced effectith a significant dose difference for PBS-PT compared to photons.
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constraint for the hippocampi is currently D40%  7.3 Gy to avoid
memory loss [10]. Prospective data demonstrate not only a signif-
icant association between increasing dose to the hippocampus and
temporal lobes and decline in neurocognitive skills following cra-
nial irradiation [26], but also with the dose and volume of the irra-
diated healthy brain and the IQ [27]. Age was also an important
determinant of impact on IQ, with younger children being more
sensitive to neurocognitive effects of RT [11,28]. Especially in this
population, a decrease in IQ, processing speed, and fine motor skills
have been reported after chemoradiation, with memory impair-
ment associated with a Dmax > 30 Gy to the temporal lobe [29].
When normal tissue volumes such as the supratentorial brain or
temporal lobes receive less of the low and intermediate doses
[28], it resulted in clinically significant higher IQ scores for patients
with intracranial tumors [30].
3.2.2. NOAR of cerebrovascular function
PBS-PT allowed for a statistically significant difference of 7.1%
Dmean and 7.8% ID of the Willis’ circle, when compared to IMRT.
El-Fayech et al. reported that at 45 years of age, the cumulative
stroke incidence was 11.3% in patients who had received
Dmean  10 Gy to the Willis’ circle as children, compared with 1%
expected from general population data [31]. In our cohort, the
Dmean applied to the Willis’ circle was 25.5 Gy (range, 10.3–
39.7 Gy) for PBS-PT, 27.5 Gy (range, 14.1–39.7 Gy) for IMRT and
27.0 Gy (range, 2.5–39.4 Gy) for VMAT. Nevertheless, the ALARA
concept seems to play an important role on the potential of
decreasing the likelihood of vascular sequelae: an association of
5% stroke hazard increase per 1 Gy (Dmean) mainly to theWillis’ cir-
cle was estimated in a longitudinal data set of >10,000 cancer sur-
vivors [32], thus showing a dose-dependent effect (almost 30-fold
higher risk of stroke after cranial RT than the general population)
[31].
3.2.3. NOAR of neuroendocrine function
Regarding the hypothalamic-pituitary axis, only the VMAT
Dmean and ID of the left hypothalamus were significantly lower
(0.6% and 0.9%, respectively) comparing with PBS-PT and Dmax
(1.2%) comparing with IMRT.
Even low dose on the hypothalamic-pituitary axis influences
the occurrence of endocrinopathy [19]. Pai et al. reported that
Dmean < 20 Gy(RBE) to the hypothalamus was associated with
endocrinopathy, even though this association was only found for
a Dmin > 50 Gy(RBE) for the pituitary gland [33]. Chemaitilly et al.
identified an association between luteinizing hormone/follicle-
stimulating hormone deficiencies already with 22 Gy Dmean to
the pituitary gland and hypothalamus on a lifetime cohort study
of adult survivors of childhood cancers [34]. In our cohort, the low-
est pituitary Dmean was achieved with IMRT, with 21.4 Gy (range,
6.2–40.1 Gy), while PBS-T 21.8 Gy (range, 2.6–41.4 Gy) and VMAT
21.6 Gy (range, 1.7–40.0 Gy). Moreover, 30 Gy Dmean to the pitu-
itary gland might cause growth hormone deficiency in  30% of
patients, with 30–50 Gy affecting 50–100% [35].
3.2.4. Other NOAR function
3.2.4.1. Vision. The lacrimal glands, lenses and optic globes could be
better spared with PBS-PT, comparing with photons (in Dmax,
Dmean, ID); yet better with IMRT, when compared to VMAT. The risk
for keratoconjunctivitis sicca could be avoided, as in all modalities
Dmean of each lacrimal gland was 25 Gy [10]. The potential for
cataract is low, as D0.03cc of each lens was 10 Gy [10], even
<6 Gy [15], according to the recommended constraints.
The risk for neuropathic complication is extremely low, consid-
ering the low optic nerve dose presented in every RT modality. The
lowest optic nerve Dmax was achieved with IMRT. However, astatistically significant difference was reached in favor of IMRT
(in Dmean and ID) only by comparing it with VMAT.
3.2.4.2. Audition. To avoid tinnitus, the Dmean of the cochleae should
be 32 Gy [10], which was possible with all three techniques. The
lowest cochlear Dmean was achieved with PBS-PT. However, a sta-
tistically significant difference was reached (in Dmax, Dmean, ID)
only by comparing IMRT with VMAT, in favor of the latter.
3.2.5. Other potential late toxicity
3.2.5.1. Radionecrosis. The Dmean applied to the brainstem was
29.9 Gy (range, 24.9–34.3 Gy) for PBS-PT, 33.0 Gy (range, 28.7–
36.3 Gy) for IMRT and 30.9 Gy (range, 28.7–36.6 Gy) for VMAT.
According to Uy et al., exceeding the 30 Gy Dmean might increase
the incidence of severe brainstem necrosis in 3% [36]. Considering
our pediatric cohort, a lower threshold should be taken into
account. The lowest brainstem dose exposure was achieved with
PBS-PT in all its dose-metrics. However, a statistically significant
difference was reached only when compared to IMRT (9.2% Dmean
and ID).
With the applied dose to the temporal lobes (3.2.1., Table 1), the
risk for necrosis is very low.
3.2.5.2. Myelopathy. Even though the spinal cord Dmax of this cohort
has not exceeded 30.2 Gy (IMRT) – therefore, not expecting the risk
of myelopathy –, the highest spinal cord sparing was achieved with
VMAT. Compared with PBS-PT and IMRT, VMAT presented reduced
Dmean (47.2%, 39.3%) and ID (45.1%, 43.1%).
3.2.5.3. Alopecia. No permanent alopecia is expected, as D0.03cc of
the skin was 25 Gy [10].
3.2.5.4. Risk for secondary malignancy. Healthy brain tissue, as a
potential risk area for secondary malignancy, could be spared
mainly with protons: Dmean 12.0 Gy (range, 8–20.5 Gy) for PBS-
PT, 18.5 Gy (range, 12.9–28.2 Gy) for IMRT and 17.9 Gy (range,
14.11–25.0 Gy) for VMAT. Despite no clinical proof of a sequelae
difference regarding this dose level to the pediatric brain, it is
known that even relatively low doses of radiation, once perceived
as being ‘‘safe”, may increase the probability of the development of
secondary cancers [37]. Therefore, the ALARA concept should be
followed. Moreover, an ID reduction, as seen in the proton plans,
is expected to result in a lower rate of secondary tumor induction
after treatment [38]. Compared to IMRT and VMAT, PBS-PT showed
the following statistically significant differences:
 normal brain (brain without PTV) – Dmax (2.5%, 1.6%), Dmean
(35.2%, –32.7%) and ID (35.2%, –33.0%, respectively);
 supratentorial brain – Dmean (23.8%, 20.7%) and ID (21.9%,
20.1%)
 parotid glands – Dmax (left: 96.7%, 93.8%; right: 98.2%,
96.6%), Dmean (100.0%, 100.0%) and ID (100.0%, 100.0%).
The dose to the parotid glands is way below the recommended
20 Gy in every modality, meaning that the expected xerostomia
will be below 20% [39]. The PBS-PT dose is otherwise close to
0.0 Gy in every dose-metric, similar to the lenses and temporo-
mandibular joints. In comparison, these healthy tissues would be
susceptible to develop a secondary malignancy if this long-term
survivor cohort would have been treated with photons.
3.3. Comparative evaluation of treatment plans
RT planning with steep dose gradient is required to better spare
the NOAR. Effective immobilization and accurate radiation delivery
methods are therefore crucial to provide the higher degree of
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tion type used and compliance of the patient. For PBS-PT plans, a
4 mm CTV-PTV margin for a bite-block immobilization system
was applied at PSI. At Inselspital, a 3 mm margin for a frameless
thermoplastic mask would have been used instead. On the one
hand, the lowest margin could be advantageous in comparison to
the 4 mmmargin by reducing the NOAR volume irradiated, mainly
from the thalamus (Supplementary file Fig. A.1, light blue VOI). On
the other hand, within this 1 mm difference, the number of NOAR
included in the PTV_Low is the same. Furthermore, the 3 mm
expansion on one TPS showed similar volume to the 4 mm expan-
sion on the other TPS, thus being cursory to perform an analysis
comparing both.
IMRT with dose painting has been shown in dosimetric compar-
isons to provide the most conformal photon treatment for WV-RT
[40,41]. However, some studies raised concern about its possibility
of creating a greater ID delivered mainly to the healthy brain [42].
Another sparing approach with photons is VMAT, with reduced
treatment delivery time compared to conventional static field
IMRT [43], which can be advantageous in a pediatric population.
For future multiple-arc treatments, dynamic trajectory VMAT
[27,44] might be a good study objective to provide further
improvements in OAR sparing in IGCT, especially when PT is not
available.
PT is an acknowledgeable technique for normal tissue sparing in
pediatric cranial RT, with its predicted consistently lower doses to
critical normal tissues and ID to the body [38] compared with pho-
tons [30]. RegardingWV-RT, MacDonald published one demonstra-
tive case of WV-RT/TB in localized IGCT (WV = 23.4 Gy, boost
45 Gy) where intensity-modulated proton therapy with fine pencil
beams (r = 3 mm) allowed additional sparing over IMRT and con-
formal PT (passive scattering or PBS) [8]. Park presented a study
with three WV-RT/TB cases (WV = 19.8 Gy, boost 30.6 Gy, normal-
ized to get 100% of the Dp to 95% of the PTV), showing similar
results [45]. Extrapolating from prospective studies [26,27], this
approach might reduce the radiation-related late toxicity in
survivors.
4. Conclusion
Taking into account the ALARA concept, PBS-PT can be a reason-
able alternative to photons for IGCT, as it seems to reduce dose
exposure to the surrounding NOAR while keeping good target cov-
erage and better conformality. Otherwise, IMRT seems dosimetri-
cally superior to VMAT regarding the NOAR sparing in WV-RT/TB.
Overall, technical attempts to potentially reduce the dose- and
volume-related side effects of treatment in long-term survivors
should be pursued, ideally on prospectively assessing outcome.
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